Stock listing

CLNN Stock Price, News, Filings & Events — Clene Inc.

Selected listing: CLNN · BOATS · USD · US

This page tracks Clene Inc.'s CLNN:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CLNN:BOATS. CLNN:BOATS is the stock-level entry point for investors researching Clene Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Clene Inc. is a public company traded under the ticker CLNN in the American market, with a market capitalization of approximately $75.6 million. The company focuses on developing innovative therapies for neurodegenerative diseases. Clene aims to improve patient outcomes through its unique approach to treatment.

CLNN:BOATSUSDUSUpdated September 11, 2026
Clene Inc. logo
Ticker
CLNN:BOATS
Asset type
Stock
Market cap
$45.9M
Sector
Health Technology
Industry
Pharmaceuticals: Major
Exchange
BOATS
Currency
USD

Clene Inc. CLNN:BOATS stock context

This page tracks Clene Inc.'s CLNN:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CLNN:BOATS. CLNN:BOATS is the stock-level entry point for investors researching Clene Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Clene Inc. is a public company traded under the ticker CLNN in the American market, with a market capitalization of approximately $75.6 million. The company focuses on developing innovative therapies for neurodegenerative diseases. Clene aims to improve patient outcomes through its unique approach to treatment.

Latest news from Clene Inc.

All Clene Inc. news →

Research Clene Inc.

Alternate listings